...

CCO Independent Conference Coverage

2009 Conference on Retroviruses and Opportunistic Infections*

February 8-11, 2009 | Montreal, Canada

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Management of Antiretroviral-Naive Patients

Track 1 of 3

Faculty:

Joel E. Gallant, MD, MPHW. David Hardy, MDKathleen E. Squires, MD
  • Joel E. Gallant, MD, MPH
  • W. David Hardy, MD
  • Kathleen E. Squires, MD

Resistance and Management of Treatment-Experienced Patients

Track 2 of 3

Faculty:

Eric S. Daar, MDJoseph J. Eron, Jr., MDKimberly Y. Smith, MD, MPH
  • Eric S. Daar, MD
  • Joseph J. Eron, Jr., MD
  • Kimberly Y. Smith, MD, MPH

HIV Highlights From Montreal

Track 3 of 3

Expert Highlights



Switch Studies From Lopinavir/Ritonavir to Raltegravir

Kimberly Y. Smith, MD, MPH, describes these interesting results from the SWITCHMRK trial. (7 minutes)


Audio File 3.25 MB

Windows Video 15.8 MB

Quicktime Video 16.3 MB

iPod Video 81.7 MB

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.

Capsule Summary:

Virologic Benefit of Directly Observed Therapy Not Maintained Among HIV-Infected Drug Users Following Switch to Self-Administered Therapy

Although virologic suppression was significantly higher following 6 months of DOT vs SAT among HIV-infected drug users, a switch from DOT to SAT for 6 additional months was associated with levels of virologic suppression comparable with those observed among patients receiving continuous SAT.

CLICK HERE TO KEEP READING

CLICK HERE FOR RELATED CAPSULE SUMMARIES